Altium Capital Management »

Annovis Bio shares owned by Altium Capital Management

Quarter-by-quarter ownership of Annovis Bio (ANVS) shares owned by Altium Capital Management from 13F filings

Historical chart of Altium Capital Management investment in Annovis Bio

Tip: Access up to 7 years of quarterly data

All positions including Annovis Bio held by Altium Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Annovis Bio by Altium Capital Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $895k 155k 5.76

More positions owned by Altium Capital Management

Vera Therapeutics Cl A (VERA)
Adma Biologics (ADMA)
Xenon Pharmaceuticals (XENE)
Intra Cellular Therapies (ITCI)
Sarepta Therapeutics (SRPT)
Insmed Com Par $.01 (INSM)
Alimera Sciences Com New
Skye Bioscience Com New (SKYE)
Argenx Se Sponsored Adr (ARGX)
Soleno Therapeutics (SLNO)
Avadel Pharmaceuticals Com Shs (AVDL)
Catalyst Pharmaceutical Partners (CPRX)
Contineum Therapeutics Cl A (CTNM)
Rezolute Com New (RZLT)
Ascendis Pharma A/s Sponsored Adr (ASND)

View all positions for Altium Capital Management

Top funds holding Annovis Bio

Citadel Advisors
Vanguard Group
Susquehanna International
LMR Partners
Altium Capital Management
BlackRock
BlackRock
Geode Capital Management
Group One Trading
Quest Partners
Wescott Financial Advisory Group
Sterling Investment Advisors
Jane Street
State Street Corporation
Merit Financial Group

View all funds holding Annovis Bio